WA AND QLD RSV IMMUNISATION PROGRAMS SHOW SIGNIFICANT REDUCTION IN INFANT HOSPITALISATIONS Consumer and HCP awareness, advocacy focus until national program decision is reversed
Filmed Perth, Western Australia | October 2024
RSV is the number one cause of hospitalisation of Australian children under five years of age, according to the Immunisation Foundation of Australia (IFA). There are mounting concerns that Australians at greatest risk of severe Respiratory Syncytial Virus, or RSV will miss out on protection against the lung infection, with the Federal Government failing to commit to a national RSV immunisation program.
Associate Professor Hannah Moore OAM, Program Head of Infections and Vaccines at the Kids Research Institute Australia, met with Australian Health Journal to discuss the impact of Respiratory Syncytial Virus (RSV) on children and immunisation showing evidence of a significant reduction in hospitalisations.
She talks about RSV causing chest infections in babies and adults, with most children being infected by the age of three. However, certain groups face higher disease rates, and infants under six months are particularly vulnerable, with up to one in 30 being hospitalised. Even older children up to five years old experience hospitalisation rates for RSV around one in 500 children.
Australian Health Journal also spoke with Catherine Hughes, the Founder and Executive Director of the Immunisation Foundation of Australia (IFA), on the need for RSV immunisations to be included in the National Immunisation Plan to ensure equitable access for vulnerable Australians. RSV immunisation programs in Western Australia and Queensland are showing promising results, leading to a significant reduction in hospitalisations. This is in contrast with the disappointment in the PBAC recently rejecting a national RSV vaccine push.
“Australia urgently needs a nationwide RSV immunisation program,” said Catherine Hughes AM, Founder and Director of the Immunisation Foundation of Australia.
IFA aims to raise awareness of RSV severity and has launched the “Unite Against RSV” campaign to provide resources for the clinical community and families. Additionally, vaccines for adults over 60 and pregnant women, as well as antibody therapy for infants, have been approved to combat RSV. The Foundation also provides regular updates on policy changes related to RSV to clinicians and other providers through its website and email subscriptions.
Efforts are being made to ensure that all Australians, especially vulnerable individuals, have access to affordable RSV immunisations. The Foundation’s advocacy work aims to include RSV immunisations on the National Immunisation Plan to guarantee easy access for all Australian families. The success of RSV immunisation programs in Western Australia and Queensland mounts the evidence on the positive impact of proactive measures in combating RSV.
-
Value of MedTech Report brings Industry and Government together
In June 2023 the Medical Technology Association of Australia (MTAA) launched The Value of MedTech Report – a major study quantifying the difference the MedTech industry makes to the lives of Australian patients, the healthcare system and the Australian economy.
Australian Health Journal spoke with MTAA CEO, Ian Burgess and MTAA Policy Manager, Pravin Siriwardena about the report and its key findings.
-
Addressing the perinatal mental health clinician shortage
Perinatal depression and anxiety (PNDA) impacts 100,000 Australians each year, equating to one in five mums and one in ten dads, with PNDA costing Australia $877 million annually. To address the nationwide shortage of specialist perinatal mental health clinicians, Gidget Foundation Australia has partnered with Federation University to launch the Graduate Diploma in Perinatal Mental Health.
-
Global MedTech company brings device reprocessing plant to Australia
Cardinal Health is global medical products manufacturer and leading provider of single-use device reprocessing services in the U.S. In Australia and New Zealand, as one of the largest suppliers of medical devices, announced on 23 May 2024 that it will be opening a single-use medical device reprocessing facility in Australia – its first reprocessing facility outside the United States.
On 18 March 2025 at the Health Innovation Living Lab at the John Hunter Hospital, a further announcement was made, on the chosen single-use medical device remanufacturing facility in Beresfield, Newcastle, set to commence operation late 2025, supported by the NSW Department of Primary Industries and Regional Development.
